---
title: "Liminatus Pharma, Inc. (LIMN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/LIMN.US.md"
symbol: "LIMN.US"
name: "Liminatus Pharma, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T12:37:44.125Z"
locales:
  - [en](https://longbridge.com/en/quote/LIMN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/LIMN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/LIMN.US.md)
---

# Liminatus Pharma, Inc. (LIMN.US)

## Company Overview

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [liminatuspharma.com](https://liminatuspharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.77 | 162 | - | - | - |
| PB | -64.31 | 541 | - | - | - |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/LIMN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/LIMN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/LIMN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/LIMN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**